Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Associated Press - October 6, 2009
Matthew Perrone, AP Business Writer
However, the FDA said Pfizer studies paint a mixed picture of its drug's effectiveness. A 48-week study comparing Selzentry to Bristol-Myers Squibb's Sustiva failed to meet the goal of showing Pfizer's drug was at least as effective at suppressing HIV.
When Pfizer reanalyzed the results using a different test to screen patients, the study met its goal.
Selzentry is currently approved as a secondary option for HIV patients who are not responding to other antiviral drugs. The company is asking the FDA to approve the drug as a first-choice treatment.
FDA scientists appeared to favor the new use in briefing documents posted online Tuesday.
The review noted "no new safety signals were identified in association" with the drug.
Selzentry carries a boxed warning about potential liver toxicity, but FDA reviewers said reports of such events were low in company trials.
On Thursday, the FDA will ask a panel of outside viral experts to vote on whether the drug appears safe and effective. The agency usually follows the group's advice, though it is not required to.
Selzentry is part of a recently developed class of treatments that block HIV from entering white blood cells through a pathway present in some patients. While more than 1 million people in the U.S. are HIV positive, only a subset of that group respond to Pfizer's pill. The drug works by blocking the so-called CCR5 receptor.
Selzentry had sales of $46 million last year, according to Pfizer.
In briefing documents posted online, the New York-based company said "there is a continuing medical need for a range of safe and well tolerated" anti-HIV drugs.
HIV attacks the body's immune system, eventually causing AIDS.
Shares of Pfizer rose 48 cents, or 2.9 percent, to $16.88 in afternoon trading.
091006
AP091005
Copyright © 2009 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .